IONIS-FB-LRx is a Antisense Oligonucleotide owned by F. Hoffmann-La Roche, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.

IONIS-FB-LRx acts by inhibiting CFB. A complement system is a group of proteins that trigger or initiate the inflammatory response. IONIS-FB-LRx by inhibiting complement factor b reduces the dry age-related macular degeneration.

The revenue for IONIS-FB-LRx is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the IONIS-FB-LRx NPV Report.

IONIS-FB-LRx was originated by Ionis Pharmaceuticals and is currently owned by F. Hoffmann-La Roche. Ionis Pharmaceuticals is the other company associated in development or marketing of IONIS-FB-LRx.

IONIS-FB-LRx Overview

IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – IONIS-FB-LRx

Report Segments
  • Innovator
Drug Name
  • IONIS-FB-LRx
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Ophthalmology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.